Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) Short Interest Down 21.6% in May

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) was the recipient of a significant decline in short interest in May. As of May 31st, there was short interest totalling 25,700 shares, a decline of 21.6% from the May 15th total of 32,800 shares. Approximately 0.5% of the company’s stock are short sold. Based on an average daily volume of 39,700 shares, the short-interest ratio is presently 0.6 days.

Institutional Trading of Hepion Pharmaceuticals

An institutional investor recently bought a new position in Hepion Pharmaceuticals stock. Armistice Capital LLC acquired a new stake in shares of Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 397,607 shares of the company’s stock, valued at approximately $1,984,000. Armistice Capital LLC owned about 10.36% of Hepion Pharmaceuticals as of its most recent SEC filing. Institutional investors and hedge funds own 17.24% of the company’s stock.

Hepion Pharmaceuticals Price Performance

Shares of Hepion Pharmaceuticals stock traded down $0.08 on Monday, reaching $1.03. 57,496 shares of the company were exchanged, compared to its average volume of 60,493. The stock’s 50 day moving average price is $1.41 and its 200-day moving average price is $2.18. The company has a market cap of $5.63 million, a P/E ratio of -0.11 and a beta of 1.70. Hepion Pharmaceuticals has a 1-year low of $0.90 and a 1-year high of $12.88.

Hepion Pharmaceuticals (NASDAQ:HEPA) last posted its quarterly earnings results on Tuesday, May 21st. The company reported ($0.56) earnings per share for the quarter.

Hepion Pharmaceuticals Company Profile

Hepion Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms.